For patients with numbers of PD-L1+ CD49f+ CD133+ CTCs ≥ 5/ml (purple line, Fig. 5C), 3-years RFS rate was 33.3% and after 67 months all patients exhibited recurrent vulvar cancer. This evidence concerns the gene CD274 and vulva cancer.